

RECEIVED
CENTRAL FAX CENTER

JUN 16 2008

FACSIMILE TRANSMISSION

DATE: JUNE 16, 2008

PAGE 1 OF:

TO: USPTO

FACSIMILE NO.: (571) 273-8300

FROM: GARY P. OAKESON

TRANSMITTED BY: BRENDA WISEMAN

OUR DOCKET NO.: 01470-24439.US

FOR: LIQUID STABLE COMPOSITION OF OXAZAPHOSPHORINE WITH MESNA

SUBJECT: AMENDMENT/RESPONSE


Commissioner For Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Attached please find an Amendment/Response for Docket No. 01470-24439.US,
Application No. 10/529,273.

Thank you. We await your confirmation of receipt.

Respectfully submitted,



Gary P. Oakeson
THORPE NORTH & WESTERN, LLP
Customer No. 20,551
Reg. No. 44266

The pages that follow may contain sensitive, privileged or confidential information intended solely for the addressee named above. If you receive this message and are not the agent or employee of the addressee, and have therefore been sent or received this communication in error, you are asked not to disseminate or copy any of the attached and are to notify the sender immediately by telephone. Please also return the original message to the sender by mail. Thank you.

JUN 16 2008

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application Number	10/529,273
Filing Date	3/25/2005
First Named Inventor	Gautam Vinod Daftary
Art Unit	1614
Examiner Name	Christopher R. Stone
Attorney Docket Number	01470-24439.US

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/Declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Thorpe North & Western, LLP		
Signature			
Printed name	Gary P. Oakeson		
Date	06/16/2008	Reg. No.	44266

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Brenda Wiseman	Date	06/16/2008

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED**CENTRAL FAX CENTER****JUN 16 2008**Application No. 10/529,273
Docket No. 01470-24439.US**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

ART UNIT: 1614
EXAMINER: Christopher R. Stone
FIRST NAMED
INVENTOR: Gautam Vinod Daftary
SERIAL NO.: 10/529,273
FILED: 3/25/2005
CONF. NO.: 2139
FOR: LIQUID STABLE COMPOSITION
OF OXAZAPHOSPHORINE
WITH MESNA
DOCKET NO.: 01470-24439.US

CERTIFICATE OF MAILING
UNDER 37 C.F.R. § 1.8**DATE OF DEPOSIT:**

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being facsimile transmitted to the USPTO or being deposited with the United States Postal Service with sufficient postage as first class mail on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda Wiseman
Brenda Wiseman

RESPONSE UNDER 37 CFR 1.111

THORPE NORTH & WESTERN, LLP
Customer No. 20,551
P.O. Box 1219
Sandy, Utah 84091-1219
Telephone: (801) 566-6633

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The present amendment and remarks are in response to the March 14, 2008 Office Action where the Examiner rejected the pending claim set. Before reconsideration of the present Application, please enter this Amendment and consider the accompanying responsive remarks.